The AHA, Federation of American Hospitals, and American Society of Health-System Pharmacists today convened a panel of experts on Capitol Hill to discuss how continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and staffing investments and identify alternative therapies.
 
Kathleen Pawlicki, vice president and chief pharmacist of Beaumont Health in Michigan and president-elect of ASHP, said the cost of staff time and resources in determining and planning contingencies for these shortages is “astronomical.” Beaumont uses the equivalent of six full-time staff – or 12,000 hours per year – to manage and monitor drug shortages.
 
The panel, which included Martin VanTrieste, president and CEO of Civica Rx – a not-for-profit generic drug company established last year by several hospitals and health systems to address shortages and high prices of medications; Jack Hoadley, research professor emeritus at Georgetown University’s Health Policy Institute; Molly Smith, AHA vice president for coverage and state issues; and Erik Rasmussen, AHA vice president of federal relations; discussed findings from a recent report prepared by NORC at the University of Chicago for the AHA, FAH and ASHP.
 
Among other findings, the report showed that average total drug spending per hospital admission increased by 18.5 percent between fiscal years 2015 and 2017, including increases in some drug classes of more than 80 percent and exceeding the Medicare payment update by fivefold.
 
To restrain out-of-control drug prices, the AHA has recommended several solutions, including stopping brand-name manufacturers' anticompetitive actions by addressing ever-greening and pay-for-delay practices, speeding up generic drug approvals, and passing the CREATES Act.

Related News Articles

Headline
The Campaign for Sustainable Rx Pricing, for which AHA is a founding member, today launched a petition and digital ad urging drug companies to suspend their “…
Headline
List prices for branded pharmaceutical products in the United States increased 159% between 2007 and 2018, an average of 9.1% per year, according to a study…
Headline
Four drugs used in hospitals for years increased their prices between 525% and 1,644% after receiving formal approval through the Food and Drug Administration’…
Headline
The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or…
Headline
The Food and Drug Administration today released the first phase of its searchable Purple Book database, which includes all FDA-approved biosimilar and…
Headline
The House Ways and Means Health Subcommittee yesterday held a hearing on proposals to lower drug prices and promote new cures.  Witness Ge Bai, an…